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$10–$35, respectively. In a group-based delivery sce-
nario, vaccination was cost-saving compared to no vac-
cine and remained so if the vaccine cost was $28/dose
(the break-even price). In the individual-based scenario,
vaccination was cost-saving if the cost was $5/dose. In
this scenario, nearly half of lost productivity in the vac-
cine group was attributable to visits to administer the
vaccine, which overshadowed the relatively modest sav-
ings in ILI-associated costs averted. CONCLUSIONS:
Routine use of intranasal influenza vaccine among healthy
children may be cost-effective and may be maximized by
using group-based vaccination approaches.
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INTRODUCTION: The American College of Chest Phy-
sicians/Society of Critical Care Medicine Consensus Con-
ference defined severe sepsis as a systemic inflammatory
syndrome in response to infection associated with acute
organ dysfunction. Often, septicemia codes have been
used in administrative datasets as a proxy for severe sep-
sis. However, these entities are not necessarily the same
and one study found large differences in mortality be-
tween septicemia patients with and without severe sepsis
(54% vs. 15%). We explored the accuracy of septicemia
codes as identifiers of severe sepsis. METHODS: We se-
lected all patients with septicemia or severe sepsis (bacte-
rial or fungal infection plus acute organ failure) in the
1996 Florida hospital discharge database (n  1,936,479)
and compared differences between the groups. Septicemia
was defined using the ICD-9-CM code 038.xxx. We de-
fined severe sepsis using a more sophisticated strategy pre-
viously validated against prospective clinical and physio-
logic criteria. RESULTS: We found 58,598 patients with
severe sepsis, 53.4% of whom were in the intensive care
unit (ICU). We found 57,875 patients with septicemia,
30.9% of whom were in the ICU. Patients with severe
sepsis had a higher mortality (24.1% vs. 18.0%, p 
0.001) and higher hospital costs ($20.4k vs. $14.4k, p 
0.001). For patients with an ICU stay, hospital mortality
was 14.4% among the 7,927 septicemia cases without se-
vere sepsis, 23.5% among the 21,655 cases of severe sep-
sis without septicemia and 42.1% among the 9,970 cases
of severe sepsis with septicemia. The mean hospital cost in
these three groups was $18,381, $24,396, and $33,470
respectively. Of all selected patients (n  99,126), 17.5%
met criteria for both septicemia and severe sepsis. The
sensitivity and positive predictive values of septicemia
codes as predictors of severe sepsis are 29.6% and 30.0%
respectively. CONCLUSIONS: Septicemia codes are not
accurate for identifying patients with severe sepsis.
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BACKGROUND: The Medi-Cal program in California
added second-generation antipsychotic medications to its
formulary in October 1997. OBJECTIVE: Investigate the
impact of the formulary expansion on patient outcomes
for olanzapine and risperidone patients before and after
the formulary expansion. STUDY POPULATION: The
study population consisted of 13,106 olanzapine and
15,718 risperidone ambulatory patients from the 100%
Medi-Cal dataset, who were classified into 3 groups.
New: no previous antipsychotic drug therapy history. Re-
starters: re-started antipsychotic drug therapy while not
on active therapy. Switcher: who switched to one of these
products while on active drug therapy. METHODS:
Models of one-year treatment costs were estimated using
both OLS regression and propensity score methods.
Models included over 85 covariates for patient demo-
graphics, prior use of services, prior antipsychotic drug
profile and diagnostic profile. Separate models were esti-
mated for the 3 patient populations. Outcomes include
total costs over one year broken down into component
costs and days of uninterrupted drug therapy achieved af-
ter re-starting therapy. RESULTS: The formulary expan-
sion immediately increased the number of new, switcher,
restarter patients starting therapy with risperidone and
olanzapine. Olanzapine patients were more likely to be
male, between the ages of 30 and 60, urban residents and
AFDC recipients. For restarters and switchers, Olanza-
pine patients also appear to be more compliant with their
prior antipsychotic drug regimen. Once these differences
were accounted for, Risperidone and olanzapine patients
exhibited similar treatment cost profiles in the post-
expansion period. CONCLUSIONS: More research is
needed to determine if the formulary expansion reduced
the cost of treating patients with schizophrenia. Further-
more, future comparison across drugs must take into ac-
count potential treatment selection bias and formulary
expansion effects on the decision to start drug therapy.
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OBJECTIVE: Antipsychotic therapies are often evaluated
on the basis of clinical endpoints (BPRS, PANSS) and
measures of direct cost. However, schizophrenia patients
